BioGend Therapeutics Co (ROCO:6733) Total Liabilities : NT$66.2 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BioGend Therapeutics Co Total Liabilities?

BioGend Therapeutics Co's Total Liabilities for the quarter that ended in Dec. 2024 was NT$66.2 Mil.

BioGend Therapeutics Co's quarterly Total Liabilities increased from Jun. 2024 (NT$63.48 Mil) to Sep. 2024 (NT$64.50 Mil) and increased from Sep. 2024 (NT$64.50 Mil) to Dec. 2024 (NT$66.19 Mil).

BioGend Therapeutics Co's annual Total Liabilities increased from Dec. 2022 (NT$90.56 Mil) to Dec. 2023 (NT$93.71 Mil) but then declined from Dec. 2023 (NT$93.71 Mil) to Dec. 2024 (NT$66.19 Mil).

BioGend Therapeutics Co Total Liabilities Historical Data

The historical data trend for BioGend Therapeutics Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioGend Therapeutics Co Total Liabilities Chart

BioGend Therapeutics Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

20.77

80.42

90.56

93.71

66.19

BioGend Therapeutics Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															93.71	65.65	63.48	64.50	66.19

BioGend Therapeutics Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BioGend Therapeutics Co's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	33.232	+	(5.836	+	27.125
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	66.2

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	912.702	-	846.509
	=	66.2

BioGend Therapeutics Co's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	33.232	+	(5.836	+	27.125
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	66.2

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	912.702	-	846.509
	=	66.2

BioGend Therapeutics Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of BioGend Therapeutics Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BioGend Therapeutics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioGend Therapeutics Co Ltd (ROCO:6733) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Yuanqu Street, 4th Floor, Number 3-2, Nangang District, Taipei, TWN, 115

Website

https://www.biogend.com.tw

BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products and the sale of related products. It is involved in the research and development of innovative cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan followed by China and other regions.

BioGend Therapeutics Co Headlines

No Headlines